Caliway Announces CBL-514 Phase 2 Study Topline Results for Dercum’s Disease, Showing 64.5% of Lipomas with Complete Clearance or Dimensions Reduction of Over 50% and Reduced Pain by 4.7

Caliway Biopharmaceuticals announced that all the primary and secondary efficacy endpoints were met in the analysis of the ITT population and PP population from the CBL-0201DD Phase 2 study, evaluating CBL-514’s efficacy and safety on participants with Dercum’s Disease lipomas.